Document is current
Any future updates will be listed below
-
Authors
Choi, Bryan D.
Yu, Xiaoling
Castano, Ana P.
Bouffard, Amanda A.
Schmidts, Andrea
Larson, Rebecca C.
Bailey, Stefanie R. https://orcid.org/0000-0002-1175-521X
Boroughs, Angela C.
Frigault, Matthew J.
Leick, Mark B.
Scarfò, Irene https://orcid.org/0000-0002-5545-3248
Cetrulo, Curtis L.
Demehri, Shadmehr
Nahed, Brian V.
Cahill, Daniel P.
Wakimoto, Hiroaki https://orcid.org/0000-0001-8225-241X
Curry, William T.
Carter, Bob S.
Maus, Marcela V. https://orcid.org/0000-0002-7578-0393
-
Funding
Funding for this research was provided by:
Neurosurgery Research and Education Foundation
Deutsche Krebshilfe
The Jenny Fund
EIF | Stand Up To Cancer
Damon Runyon Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 10 January 2019
Accepted: 14 June 2019
First Online: 22 July 2019
Competing interests
: B.D.C. and M.V.M. are inventors on patents related to the use of engineered cell therapies and bispecific T-cell engagers for GBM and other cancers. B.D.C. received commercial research grants from ACEA Biosciences. M.V.M. received commercial research grants from Kite Pharma, TCR2, Agentus and CRISPR Therapeutics (unrelated to this work), and is a consultant or advisory board member for Adaptimmune, Agentus, Cellectis, CRISPR Therapeutics, Kite Pharma, Novartis, TCR2 and Windmil (unrelated to this work).
